BioNexus Gene Lab (BGLC) Long-Term Deferred Tax (2021 - 2026)

BioNexus Gene Lab (BGLC) reported Long-Term Deferred Tax of $12.2 million for Q1 2026, up 29.33% sequentially from $9.4 million in Q4 2024.

BioNexus Gene Lab (BGLC) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends

BioNexus Gene Lab (BGLC) has 3 years of Long-Term Deferred Tax data on file, last reported at $12.2 million in Q1 2026.

For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (changed N/A YoY), and the FY2024 full-year result was $9.4 million, changed N/A from the prior year.
Long-Term Deferred Tax advanced to $12.2 million in Q1 2026, from $9.4 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $12.2 million in Q1 2026 to a low of $9.4 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Linde	237.95 Bn	233.99 Bn	4.26 Bn
2	Sherwin Williams	78.17 Bn	77.95 Bn	2.78 Bn
3	Ecolab	76.02 Bn	75.37 Bn	1.85 Bn
4	Air Products & Chemicals	66.38 Bn	65.43 Bn	987.40 Mn
5	Ppg Industries	26.02 Bn	24.40 Bn	1.66 Bn
6	LyondellBasell Industries	22.51 Bn	19.87 Bn	701.00 Mn
7	Chemical & Mining Co Of Chile	19.70 Bn	15.83 Bn	778.60 Mn
8	International Flavors & Fragrances	19.51 Bn	18.95 Bn	1.02 Bn
9	DuPont de Nemours	18.80 Bn	18.71 Bn	602.00 Mn
10	BioNexus Gene Lab	2.82 Mn	-1.14 Mn	-790.00

Download Data